Fig. 8From: Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticlesFluorescent images of SKBR3 cells treated with no sample (a), Herceptin and secondary antibody-FITC(b), dye-doped TWORM nanoparticles (c), dye-doped Herceptin-conjugated TWORM nanoparticles (d), dye-doped AOTORM nanoparticles (e), and dye-doped Herceptin-conjugated AOTORM nanoparticles (f)Back to article page